Vivo Bio Tech Q1 FY27 Results: Revenue Up 14%, PAT Falls 86% YoY

Ebitda Margin CompressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.7%Reaction day

₹25.54

prior close

₹25.05

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-7.7% vs market

Pharmaceuticals & Biotechnology peers, median of 171sector · industry level-0.2%-8.5% vs sector

On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250 and 8.5 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.3

10m

-2.1

15m

-0.6

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.7-1.0-7.7-0.2-8.5

Next day

-9.3-0.4-9.0-0.2-9.1

-7.8-0.8-7.0-0.3-7.5

-8.0-1.9-6.1-1.2-6.7

-6.4-1.3-5.1-0.8-5.6

-8.0-1.0-7.0-0.7-7.3

-9.9-2.8-7.2-2.9-7.1

15d

-15.6+0.4-16.0-2.1-13.5

-20.3+2.4-22.7-0.9-19.5

—+1.0—-1.1—

—+1.8—-2.7—

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivo Bio Tech posted Q1 FY27 (ended June 30, 2026) consolidated revenue of Rs. 1,427.97 lacs, up about 14% YoY from Rs. 1,251.16 lacs. However, net profit crashed to Rs. 18.76 lacs from Rs. 133.71 lacs in Q1 FY26, a fall of about 86%, as employee costs rose 48%, depreciation rose 34%, and administrative expenses grew. PBT fell to Rs. 33.86 lacs from Rs. 147.99 lacs. EPS dropped to Rs. 0.08 from Rs. 0.74. Standalone numbers are similar. Auditor P. Murali & Co. gave a clean limited review report. Single segment: Bio Technology.

Likely market impact

Sharp profit fall despite revenue growth signals heavy cost pressure and weak operating leverage, which may weigh on the stock despite topline expansion.